A novel role for tumor necrosis factor-α in regulating susceptibility of activated CD4+ T cells from human and nonhuman primates for distinct coreceptor using lentiviruses

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 1, 2000, Pages 10-22

  Brice, G T ^a   Mayne, A E ^a   Villinger, F ^a   Ansari, A A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokines; Coreceptor usage; Cytokines; Mode of CD4+ T cell activation; TNF

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION SENSITIVITY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS RESISTANCE;

EID: 0034190720     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200005010-00003     Document Type: Article

References (81)

1. Alkhatib G, Combadiere CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC-CKR5: a RANTES MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8.
2. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996;272:872-7.
3. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381:661-6.
4. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58.
5. Choe H, Farzan M, Sun Y, The β-chemokine receptors CCR3 and CCR5 facilitate infection by HIV-1 isolates. Cell 1996;85:1135-48.
6. Asjo B, Morfeldt-Manson L, Albert J, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;2:660-2.
7. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-19.
8. Tersmette M, Gruters RA, de Wolf F, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989;63:2118-15.
9. Schellekens PT, Koot M, Roos MT, Tersmette M, Miedema F. Immunological and virological markers determining progression to AIDS. Neth J Med 1994;45:238-43.
10. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
11. Koot M, vant Wout AB, Koostra NA, de Goede Ra, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996;173:349-54.
12. Richman DD, Bozzette S. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
13. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32:364-70.
14. Jourdan P, Abbal C, Nora N, et al. IL-4 induces functional cell-surface expression of CXCR4 on human T cells. J Immunol 1998; 160:4153-7.
15. Valentin A, Lu W, Rosati M, et al. Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998;95:8886-91.
16. Wang J, Roderiguez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998;72:7642-7.
17. Torres Y, Medrano FJ, Rey C, et al. Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype. Eur J Clin Invest 1998;28: 930-6.
18. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-65.
19. Clerici M, Shearer GM. A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14: 107-11.
20. Villinger F, Brar SS, Brice GT, et al. Immune and hematopoietic parameters in HIV-1 infected chimpanzees during clinical progression towards AIDS. J Med Primatol 1997;26:11-8.
21. Brice GT, Riley JL, Villinger F, et al. Development of an animal model for autotransfusion therapy: in vitro characterization and analysis of anti-CD3/CD28 expanded cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:210-20.
22. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272:1939-43.
23. + T lymphocytes by CD28 costimulation modulates human immunodeficiency virus type 1 (HIV-1) entry cofactor expression and susceptibility to HIV-1 infection. Science 1997;276:273-6.
24. Riley JL, Carroll RG, Levine BL, Bernstein W, St. Louis DL, Weislow OS. Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J Immunol 1997;158:5545-53.
25. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996;184:569-77.
26. Schrum S, Probst P, Fleischer B, Zipfel PF. Synthesis of the CC-chemokines MIP-1α, MIP-1β, and RANTES is associated with a type-1 immune response. J Immunol 1996;157:3598-604.
27. Walker CM, Moody DJ, Stites DP, Levy LA. CD8 lymphocytes can control HIV-1 replication in vitro by suppressing virus replication. Science 1986;234:1563-6.
28. + lymphocytes. J Immunol 1988;140:2237-42.
29. + T cells: evidence for a soluble factor. J Immunol 1990;144:2961-6.
30. + T cells derived from non-human primates. Clin Exp Immunol 1993;91:473-81.
31. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995;92:2308-13.
32. + T cells. Science 1995;270:1811-3.
33. Polacino PS, Liang HA, Clark EA. Formation of simian immunodeficiency virus long terminal repeat circles in resting T cells requires both T cell receptor- and IL-2-dependent activation. J Exp Med 1995;182:617-21.
34. Polacino PS, Liang HA, Firpo EJ, Clark EA. T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques. J Virol 1993;67: 7008-16.
35. + T cells requires a Cyclosporin A-sensitive pathway. J Immunol 1997;158:512-7.
36. Harouse JM, Tan RC, Gettie A, et al. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 1998;248:95-107.
37. Forster R, Kremmer E, Schubel A, et al. Intracellular and surface expression of HIV-1 coreceptor CXCR4/Fusin on various leukocytes subsets: rapid internalization and recycling upon activation. J Immunol 1998;160:1522-31.
38. Sattentau Q, Weiss R. The CD4 antigen: physiological ligand and HIV receptor. Cell 1988;52:631-3.
39. Bleul CC, Wu LJ, Hoxie JA, Springer TA, Mackay CR. The HIV co-receptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94:1925-30.
40. Riley JL, Levine BL, Craighead N, et al. Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation:implications for transmission and pathogenesis. J Virol 1998;72:8273-80.
41. + T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virology 1999;73:6430-5.
42. Hengel RL, Jones BM, Kennedy MS, Hubbard MR, McDougal JS. Markers of lymphocyte homing distinguish CD4 T cell subsets that turnover in response to HIV-1 infection in humans. J Immunol 1999;163:3539-48.
43. + T ymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation. J Virol 1999;73:7515-23.
44. Fais S, Lapenta C, Santini SM, et al. Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/ differentiation of human target cells at the time of primary infection. J Virol 1999;73:6453-9.
45. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998;178:1279-87.
46. Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998;72:3161-8.
47. Gummuluru S, Emerman M. Cell cycle and Vpr-mediated regulation of human immunodeficiency virus type I expression in primary and transformed T-cell lines. J Virol 1999;73:5422-30.
48. Gozlan J, Lathey JL, Spector SA. Human immunodeficiency virus type 1 induction mediated by genistein is linked to cell cycle arrest in G2. J Virol 1998;72:8174-80.
49. Tobiume M, Fujinaga K, Kameoka M, et al. Dependence on host cell cycle for activation of human immunodeficiency virus type 1 gene expression from latency. J Gen Virol 1998;79:1363-71.
50. Poll G. Cytokines and the human immunodeficiency virus: from bench to bedside. Eur J Clin Invest 1999;29:723-32.
51. Galli GF, Annunziato C, Mavilia P, et al. Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-gamma of fusin/CXCR4. Ear J Immunol 1998;28:3280-90.
52. + T-helper 1 (Th1) and Th2-type conditions. J Virol 1999;73:316-24.
53. Greco G, Mackewicz C, Levy JA. Sensitivity of human immunodeficiency virus infection to various alpha, beta, and gamma chemokines. J Gen Virol 1999;80:2369-73.
54. Husman A de R, Blaak H, Brouwer H, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999;163:4597-603.
55. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83.
56. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosia D, et al. Differential expression of chemokine receptors and chemotactic tesponsiveness of type 1 T helper cells (This) and Th2s. J Exp Med 1998;187:129-34.
57. Spira AI, Ho DD. Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J Virol 1995;69:422-9.
58. Wainberg MA, Blain N, Fitz-Gibbon L. Differential susceptibility of human lymphocyte cultures to infection by HIV-1. Clin Exp Immunol 1987;70:136-42.
59. Kabat D, Kozak SI, Wehrly K, Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 1994;68:2570-6.
60. Tersmette M, de Goede REY, Al BJM, et al. Differential syncytium inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS related complex. J Virol 1988;62:2026-32.
61. Schuitemaker H, Koot M, Koostra NA, Wouter-Dercksen M, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol 1992;66:1354-60.
62. Cheng-Mayer C, Quiroga M, Tung JW, Dina D, Levy JA. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 1990;64:4390-8.
63. Lane BR, Markovitz DM, Woodford NL, Rochford R, Streiter RM, Coffey MJ. TNF-a inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 1999;163:3653-61.
64. Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall TJ, et al. Regulation of the production of the RANTES chemokine by endothelial cells: synergistic induction by IFN-gamma plus TNF-α and inhibition by IL-4 and IL-13. J Immunol 1995;154:1870-8.
65. Mellors J, Griffith B, Ortiz M, Landy M, Ryan J. Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type I replication in primary macrophages. J Infect Dis 1991;163: 78-85.
66. Michihiko S, Yamamoto N, Shinozaki F, Shimada K, Soma G, Kobayashi N. Augmentation of in vitro HIV replication in peripheral blood mononuclear of AIDS and ARC patients by tumor necrosis factor. Lancet 1989;27:1206-8.
67. Lahdevirta J, Maury C, Teppo A, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-97.
68. Ugolini S, Moulard M, Mondor I, et al. HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4. J Immunol 1997;159:3000-8.
69. Xiao X, Stantchev TS, Feng YR, Ugolini S, et al. Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci USA 1999;96:7496-7501.
70. + T cell activation induced human immunodeficiency virus replication. Infect Immunol 1999;67:5258-64.
71. Zhang L, He T, Huang Y, et al. Chemokine co-receptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 1998;73:9307.
72. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Hemophilia Growth and development Study. Multicenter AIDS Cohort Study. Science 1996;273:1856-62.
73. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:668-70.
74. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
75. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-93.
76. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-8.
77. Doranz BJ, Grovit-Ferbas K, Sharron MP, et al. A small molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 co-receptor. J Exp Med 1997;186:1395-1400.
78. Bostik P, Villinger F, Brice GT, et al. Expression and in vitro evaluation of rhesus macaque wild type (wt) and modified CC chemokines. J Med Primatol 1998;27:121-8.
79. Murakami T, Zhang T-Y, Koyanagi Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999;73:7489-96.
80. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1991;216:216-9.
81. Arenzana-Seisdedos F, Virelizer J-L, Rousselt D, et al. HIV blocked by chemokine antagonist. Nature 1996;383:400-2.